EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

PROTACs: A novel strategy for cancer drug discovery and development

Xin Han, Yi Sun

MedComm · 2023-06 · 4 (3)

DOI: 10.1002/mco2.290 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift MedComm, online erschienen am 29.05.2023. Verfasst von Xin Han und 1 weiteren Autor:innen. Beteiligte Einrichtung: Cancer Institute (Key Laboratory of Cancer Prevention and Intervention China National Ministry of Education) of the Second Affiliated Hospital and In…. Die Arbeit wurde bisher 64-mal zitiert (Crossref) und nennt 431 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Proteolysis targeting chimera (PROTAC) technology has become a powerful strategy in drug discovery, especially for undruggable targets/proteins. A typical PROTAC degrader consists of three components: a small molecule that binds to a target protein, an E3 ligase ligand (consisting of an E3 ligase and its small molecule recruiter), and a chemical linker that hooks first two components together. In the past 20 years, we have witnessed advancement of multiple PROTAC degraders into the clinical trials for anticancer therapies. However, one of the major challenges of PROTAC technology is that only very limited number of E3 ligase recruiters are currently available as E3 ligand for targeted protein degradation (TPD), although human genome encodes more than 600 E3 ligases. Thus, there is an urgent need to identify additional effective E3 ligase recruiters for TPD applications. In this review, we summarized the existing RING‐type E3 ubiquitin ligase and their small molecule recruiters that act as effective E3 ligands of PROTAC degraders and their application in anticancer drug discovery. We believe that this review could serve as a reference in future development of efficient E3 ligands of PROTAC technology for cancer drug discovery and development.

Schlagwörter

Stichwörter der Autor:innen

E3 ligase ligandsPROTAC degraderstargeted therapy

Autor:innen und Institutionen

  • Cancer Institute (Key Laboratory of Cancer Prevention and Intervention China National Ministry of Education) of the Second Affiliated Hospital and Institute of Translational Medicine Zhejiang University School of Medici…
  • Cancer Center of Zhejiang University Hangzhou China.
  • Zhejiang Provincial Clinical Research Center for CANCER Zhejiang Province China.
  • Key Laboratory of Molecular Biology in Medical Sciences Zhejiang Province China.
  • Research Center for Life Science and Human Health Binjiang Institute of Zhejiang University Hangzhou China.

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Han, X., & Sun, Y. (2023). PROTACs: A novel strategy for cancer drug discovery and development. MedComm, 4(3). https://doi.org/10.1002/mco2.290

Vancouver

Han X, Sun Y. PROTACs: A novel strategy for cancer drug discovery and development. MedComm. 2023;4(3). doi:10.1002/mco2.290

BibTeX
@article{Han2023,
  author = {Han, Xin and Sun, Yi},
  title = {PROTACs: A novel strategy for cancer drug discovery and development},
  journal = {MedComm},
  year = {2023},
  volume = {4},
  number = {3},
  doi = {10.1002/mco2.290}
}
Kostenlos starten →